Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

PURETECH HEALTH PLC (PRTC)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Sector news Biotechnology & Medical Research - NEC
02:59pGILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
05/25Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe
RE
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
05/08UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing
RE
05/03Teva raises 2018 outlook, expects migraine drug approval by year-end
RE
05/03Samsung BioLogics' shares slide again; unit's valuation jump questioned
RE
05/02NOVARTIS : Gets Second FDA Approval for CAR-T Cancer Drug
DJ
05/01GILEAD SCIENCES : Quarterly Results Miss Wall Street Expectations -- Earnings Re..
DJ
04/26GILEAD SCIENCES : The Million Dollar Cancer Treatment No One Knows How to Pay fo..
DJ
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/06Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda
DJ
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/11REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10Prisons Expand Hepatitis Treatment -- WSJ
DJ
03/09More Prison Inmates Get Access to Hepatitis-C Drugs
DJ
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/08FTSE slides after BOE meeting as pound pops higher
RE
02/08REGENERON PHARMACEUTICALS : Collaborations Drive Revenue Increase at Regeneron -..
DJ
02/07GlaxoSmithKline sees light at end of Advair tunnel
RE
02/06GILEAD SCIENCES : Reports Quarterly Loss Driven by Tax Charge -- Earnings Review
DJ
01/30Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
01/22Biotech M&A takes off as Sanofi and Celgene spend $20 billion
RE
01/22New drugs recast $10 billion haemophilia market as Sanofi swoops in
RE
01/12Drugmakers see a pricing blueprint in an $850,000 gene therapy
RE
01/12SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
RE
01/08$11 billion biotech binge fuels forecasts of 2018 M&A surge
RE
01/08SANOFI : and Regeneron boost investment in cancer drug cemiplimab
RE
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
DJ
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance
DJ
01/05Best week since April for European shares as UK, Swiss indexes hit records
RE
01/02New drug approvals hit 21-year high in 2017
RE
2017U.S. tax cuts mix pleasure and pain for Europe's dollar earners
RE
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 3,50 M
EBIT 2018 -131 M
Net income 2018 -68,3 M
Debt 2018 46,1 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 176x
EV / Sales 2019 379x
Capitalization 568 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
PURETECH HEALTH PLC3.33%568
CELLTRION, INC.--.--%34 574
IQVIA HOLDINGS INC8.22%21 638
LONZA GROUP1.10%20 183
INCYTE CORPORATION-23.96%15 266
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 678
SEATTLE GENETICS, INC.22.90%10 403
NEKTAR THERAPEUTICS-3.95%10 012
EXACT SCIENCES CORPORATION30.43%8 528
QIAGEN NV6.08%8 485
ALKERMES PLC-7.24%7 871
SAGE THERAPEUTICS INC-1.59%7 572
ICON PLC20.78%7 250
PRA HEALTH SCIENCES INC5.66%6 165
BIO-TECHNE CORP27.81%6 150
CHARLES RIVER LABORATORIES INTL. INC7.13%5 585
IONIS PHARMACEUTICALS INC-13.31%5 473
GALAPAGOS5.57%5 034
UNITED THERAPEUTICS CORPORATION-21.89%5 032
FIBROGEN INC30.38%4 986
SYNEOS HEALTH INC11.58%4 887